FDA-approved small-molecule kinase inhibitors

Area of Science:

• Pharmacological Research
• Medicinal Chemistry
• Oncology

Background:

• Kinases are crucial in cellular signaling and are highly sought-after drug targets, particularly for cancer treatment.
• The US Food and Drug Administration (FDA) has approved 28 small-molecule kinase inhibitors, with half approved in the last three years, indicating rapid advancement in the field.

Purpose of the Study:

• To provide a comprehensive review of all FDA-approved small-molecule kinase inhibitors.
• To analyze the binding mechanisms and structural features of these inhibitors.
• To summarize current achievements, challenges, and future directions in kinase inhibitor research.

Main Methods:

• Systematic review of FDA-approved small-molecule kinase inhibitors.
• Analysis of binding mechanisms and structure-activity relationships (SAR).
• Literature review to identify current trends and challenges.

Main Results:

• A comprehensive list of 28 approved small-molecule kinase inhibitors is presented.
• Detailed analysis of binding modes and key structural characteristics influencing inhibitor efficacy.
• Identification of emerging trends and persistent challenges in the development of kinase inhibitors.

Conclusions:

• Small-molecule kinase inhibitors represent a significant advancement in cancer therapy.
• Understanding binding mechanisms and structural features is key to developing more effective inhibitors.
• Continued research is essential to overcome current challenges and explore future directions in kinase inhibitor drug discovery.